News

Cardio3 Biosiences goes public
Enlarge image

BusinessBelgium

Cardio3 Biosiences goes public

05.06.2013 - After having raised €19m, Belgian reg-med specialist Cardio3 BioSciences has hunger for more. The company announced to go public.

Only two weeks after a capital increase, the company said it will launch an IPO at NYSE Euronext Brussels and NYSE Euronext Paris to raise new funds. Cardio3 BioSciences' lead product C-CureR (C3BS-CQR-1) has been moved to Phase III development following promising results.

Through a process called cardiopoiesis, the company can reprogramme bone marrow cells to become heart precursor cells. Cardio3 BioSciences wants to use them to repair heart failure secondary to ischemic heart disease. The IP was licenced from the US Mayo Clinic (Rochester, Minnesota).  

Heart failure is one of the world's greatest unmet medical needs. At 40 years old, a person has a one in five risk of developing heart failure and, once the disorder is apparent, a one in three chance of dying within a year of diagnosis. US$32bn annually is spent on heart failure patients in the US alone.  

C3BS-CQR-1 is currently being tested in Europe in the CHART-1 trial, the world's first phase III trial using pre-programmed cardiac progenitor cells for the treatment of heart failure. Phase II results pointed to an increase of 25% of the Left Ventricular Ejection Fraction (LVEF) which was statistically significant (p<0.0001), as was the increase in exercise capacity measured by the 6 minutes Walking Distance test (+77m change at 6 months versus baseline in comparison to the control group (p<0.01). Cardio3 BioSciences intends to start a trial in the US (the CHART-2 trial if the FDA authorizes its start. The CHART programme is designed as two pivotal studies to obtain marketing authorisation in Europe and in the USA respectively, either alone, or in combination with other clinical trials.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/cardio3-biosiences-goes-public.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NORDIC NANOVECTOR (N)24.00 NOK23.71%
  • TRANSGENE (F)4.72 EUR23.56%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%

FLOP

  • THROMBOGENICS (B)3.09 EUR-20.97%
  • ZELTIA (E)3.35 EUR-12.76%
  • OXFORD BIOMEDICA (UK)8.00 GBP-12.09%

TOP

  • KARO BIO (S)38.50 SEK2383.9%
  • TRANSGENE (F)4.72 EUR63.9%
  • BIOTECH PHARMACON (N)12.50 NOK33.7%

FLOP

  • THROMBOGENICS (B)3.09 EUR-42.4%
  • WILEX (D)2.05 EUR-41.4%
  • BIONOR PHARMA (N)1.26 NOK-39.4%

TOP

  • KARO BIO (S)38.50 SEK4595.1%
  • ADOCIA (F)87.65 EUR439.1%
  • GALAPAGOS (B)54.02 EUR324.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.84 EUR-76.1%
  • NEOVACS (F)0.89 EUR-74.9%

No liability assumed, Date: 27.08.2015